9 August 2024
Higher costs are limiting MOH’s budget for key first-line chemotherapy drugs, such as topotecan (for retinoblastoma, neuroblastoma), temozolomide (for high-grade glioma), as well as pegaspargase and arsenic trioxide (for acute leukaemia).